Clinical Trial

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.
Trial Details
NCT Number NCT06553339
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Enrollment 60 participants
Start Date 2024-07-19
Primary Completion 2026-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-14